Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

12.95 +0.02 (+0.15%)
Streaming Delayed Price Updated: 12:23 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,722
Open 13.23
Bid (Size) 12.59 (1)
Ask (Size) 12.95 (1)
Prev. Close 12.93
Today's Range 12.85 - 13.40
52wk Range 6.710 - 17.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-18.8%
-18.8%
1 Month
+34.6%
+34.6%
3 Month
+9.9%
+9.9%
6 Month
-18.8%
-18.8%
1 Year
-18.8%
-18.8%

More News

Read More
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
From Maze Therapeutics, Inc.
Via GlobeNewswire
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Chanson International Holding Shares Are Trading Higher By Around 170%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
From Maze Therapeutics, Inc.
Via GlobeNewswire
Infinity Natural Resources Valued At $1.3 Billion In Market Debut
Via Talk Markets
Topics Energy Stocks / Equities
Exposures Fossil Fuels

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 12.95
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 06/09/25 12:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.